Cytokine Network

Izuhara, Kenji; Nunomura, Satoshi; Ogawa, Masahiro; Nanri, Yasuhiro

doi:10.1007/978-981-10-5541-6_9

Cited by 1 publication

(1 citation statement)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It seems that a key factor in understanding the nature of the inflammation underlying this disease is the assessment of changes at the molecular level (Hacker, Hoermann, & Kenner, ; Salto‐Tellez, ; Zhao et al, ). Molecular diagnostics is becoming more and more common, thanks to the increased availability of this type of analysis and the observation of complex interactions between individual cytokines and related signaling pathways (Izuhara, Nunomura, Ohta, Ogawa, & Nanri, ; Ngo et al, ; Reali & Brembilla, ). Molecular assessment in relation to psoriasis is not only about its diagnosis, but is used to monitor the effectiveness of a given therapy and assess its safety profile (Villanova, Di Meglio, & Nestle, ).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of expression pattern of selected genes associated with IL12/23 signaling paths in psoriatic patients during cyclosporine A therapy

Grabarek

Wcisło‐Dziadecka

Michalska-Bańkowska³

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Molecular analysis is key to a better understanding of drug resistance during therapy. The aim of this study was to evaluate changes in the expression of tumor necrosis factor α (TNF‐α), interleukin (IL)—IL12A, IL12B, IL23A, interferon gamma (IFN‐γ) in psoriatic patients during 84 days of treatment and TNF‐α on the protein level. The study group consisted of 32 psoriatic patients during cyclosporine A therapy. The molecular analysis was made by using real‐time reverse transcription polymerase chain assay (RTqPCR) and MALDI ToF mass spectroscopy three times: after 0, 42, 84 days of treatment. Statistically significant differences (p < .05) in transcriptional activity were observed for genes: TNF‐α (0 vs. 42nd days p = .006; 0 vs. 84th days p = .005), IL23A (0 vs. 42nd days p = .041), IFN‐γ (0 vs. 42th days p = .040; 0 vs. 84th days p = .041), IL17 (0 vs. 42nd p = .000003 0 vs. 84th p = .001650), IL12A (0 vs. 42nd p = .0047 vs. 84th p = .0063). The expression of TNF‐α was downregulated during therapy, IL23A was upregulated during CsA treatment, while the expression of IFN‐γ and IL17 were higher after 42 days and lower after 84 days compared to 0 days of CsA treatment. It seems that TNF‐α, IL12A, IL23A, IFN‐γ, and IL17 can be useful complementary molecular markers to assess the efficacy of psoriasis treatment.

show abstract